Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

HHS Secretary Alex Azar Talks Rebate Changes, But Not Eliminating Discounts Altogether

Details on anticipated changes to rebate practices are in demand. HHS Secretary Azar talked about changes that would still allow negotiated discounts at the point of sale during a presentation at the FT Pharma Pricing and Value Summit.

Market Access Pricing Debate Reimbursement

Latest From Pricing Debate

Trump Administration's Rx-Price-Disclosure Reg Sets Up Legal Fight With PhRMA

From kinds of ads targeted to agency that's issuing the reg, policy seems designed to withstand a court challenge.
Advertising, Marketing & Sales Pricing Debate

PhRMA’s Defensive Move On DTC Ads: Putting Drug List Prices ‘In Context’

Member companies’ direct-to-consumer TV ads will direct patients to information about drug costs – including list price, estimated out-of-pocket costs for the drug, and availability of financial assistance – under a voluntary program that takes effect in April 2019; initiative falls short of mandatory list price disclosures proposed by Trump Administration.

Pricing Debate Advertising, Marketing & Sales

Industry Makes A Drug Price Transparency Push In DTC Ads, But Is It Too Little Too Late?

PhRMA unveiled a voluntary policy under which drug makers will provide information in DTC ads about how to access drug prices and cost information. But hours later HHS issued a proposed rule on the same topic, only requiring drug makers to include WAC prices in TV ads. .

Pricing Debate Advertising, Marketing & Sales

Step Therapy For Anti-Inflammatories, ESAs Coming To UnitedHealthcare Medicare Plans

Remicade, Procrit, Aranesp and biosimilars will be subject to step therapy in limited number of Medicare Advantage plans in 2019.

Pricing Debate Medicare

US FDA Sets Generic Approval Record, But Generic Sponsors Aren't Celebrating

FDA relates new record to its plan to increase access to affordable drugs, but Association for Accessible Medicines says approvals alone will not increase competition.
Generic Drugs Pricing Debate

Nordic Procurement Deal Signals New Weapons In Fight For Lower Prices

A new joint procurement agreement between Norway and Denmark is a signal to drug companies that they will have to increasingly negotiate with more than one country in a new age of collaboration, says Amgros, the Danish medicines procurement agency.

Europe Denmark

US Drug Pricing Challenges Poised To Impact Pharma Growth, Leerink Warns

Drug price increases have contributed significantly to US revenue growth, about 61% for the 45 largest pharmaceutical products sold over the last three years, according to an analysis by Leerink. Investors should brace for declining growth rates for certain products that generate the bulk of their sales in the US, analyst Geoffrey Porges warned.

Pricing Debate Business Strategies

Vertex Extends Portfolio Pricing and Reimbursement Approach To Denmark

Vertex has succeeded in bringing its portfolio-based approach to the pricing and reimbursement of its cystic fibrosis treatments to another market, Denmark. This follows similar deals in Ireland and Sweden.

Europe Denmark

VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching

Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
Biosimilars Pricing Debate
See All
Advertisement
UsernamePublicRestriction

Register